Regulatory perspective on translating proteomic biomarkers to clinical diagnostics

Journal of Proteomics

Volumn 74, Issue 12, 2011, Pages 2682-2690

  Li, Jinong ^a   Kelm, Kellie B ^a   Tezak, Zivana ^a  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

Complex tests; Device regulation; Food and Drug Administration; In vitro diagnostics; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

DIAGNOSTIC ACCURACY; EQUIPMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; MARKETING; MASS SPECTROMETER; MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUALITY CONTROL; REVIEW;

ANIMALS; CLINICAL LABORATORY TECHNIQUES; HUMANS; MASS SPECTROMETRY; PROTEOMICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 81055156170     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.07.028     Document Type: Review

References (49)

1. FDA. Chapter I-Food and Drug Administration, Department of Health and Human Services. Subchapter H-Medical devices. Part 809-In vitro diagnostic products for human use. Subpart A-General provisions. Sec. 809.3 Definitions. In: FDA. CFR - Code of Federal Regulations Title 21. Title 21-Food and drugs. Vol. 8. Accessed August 2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR_809.3.
2. FDA. Sec. 513. [21 USC §360c]. Classification of devices intended for human use; device classes. , See (a)(1) section. Accessed August 2011. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm110188.htm.
3. FDA. How To Find A Predicate Device. Accessed August 2011. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm134571.htm.
4. FDA. Chapter I-Food and Drug Administration, Department of Health and Human Services. Subchapter H-Medical devices. Part 860-Medical device classification procedures. Subpart A-General. Sec. 860.7 Determination of safety and effectiveness. In: FDA. CFR - Code of Federal Regulations Title 21. Title 21-Food and drugs. Vol. 8. Accessed August 2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?FR_860.7.
5. FDA. Chapter I-Food and Drug Administration, Department of Health and Human Services. Subchapter H-Medical devices. Part 820-Quality system regulation. In: FDA. CFR - Code of Federal Regulations Title 21. Title 21-Food and drugs. Vol. 8. Accessed August 2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart_820&showFR_1.
6. FDA. Chapter I-Food and Drug Administration, Department of Health and Human Services. Subchapter H-Medical devices. Part 812-Investigational device exemptions. Accessed August 2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?cfrpart=812.
7. FDA. Chapter I-Food and Drug Administration, Department of Health and Human Services. Subchapter H-Medical devices. Part 814- Premarket approval of medical devices, subpart H-Humanitarian use devices. Accessed August 2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=814&showFR=1.
8. Paulovich A.G., Whiteaker J.R., Hoofnagle A.N., Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008, 2:1386-1402.
9. Carr S.A., Anderson L. Protein quantitation through mass spectrometry: the way out of biomarker purgatory?. Clin Chem 2008, 54:1749-1752.
10. Campbell A.M. Production and purification of antibodies. Immunoassays 1996, 96-115. Academic Press, San Diego. E.P. Diamandis, T.K. Christopoulos (Eds.).
11. Kitteringham N.R., Jenkins R.E., Lane C.S., Elliott V.L., Park B.K. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1229-1239.
12. Yocum A.K., Chinnaiyan A.M. Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief Funct Genomic Proteomic 2009, 8:145-157.
13. Lange V., Picotti P., Domon B., Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222-235.
14. Han B., Higgs R.E. Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Brief Funct Genomic Proteomic 2008, 7:340-354.
15. Lin S., Shaler T.A., Becker C.H. Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in single-quandrupole ion trap. Anal Chem 2006, 78:5762-5767.
16. Barr J.R., Maggio V.L., Patterson D.G., Cooper G.R., Henderson L.O., Turner W.E., et al. Isotope-dilution mass spectrometric quantification of specific proteins: model application with apolipoprotein A-1. Clin Chem 1996, 42:1676-1682.
17. Barnidge D.R., Dratz E.A., Martin T., Bonilla L.E., Moran L.B., Lindall A. Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards. Anal Chem 2003, 75:445-451.
18. Gerber S.A., Rush J., Stemman O., Kirschner M.W., Gygi S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem mass spectrometry. Proc Natl Acad Sci 2003, 100:6940-6945.
19. Barnidge D.R., Goodmanson M.K., Klee G.G., Muddiman D.C. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution MS. J Proteome Res 2004, 3:644-652.
20. 13C-labeled peptide standards. Proteomics 2004, 4:1175-1186.
21. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5:573-588.
22. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007, 6:2212-2229.
23. Aguiar M., Masse R., Gibbs B.F. Mass spectrometric quantitation of C-reactive protein using labeled tryptic peptides. Anal Biochem 2006, 354:175-181.
24. Addona T.A., Abbatiello S.E., Schilling B., Skates S.J., Mani D.R., Bunk D.M., et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641.
25. Hoofnagle A.N. Quantitative clinical proteomics by liquid chromatography-tandem mass spectrometry: assessing the platform. Clin Chem 2010, 56:161-164.
26. Qian W.J., Jacobs J.M., Liu T., Camp D.G., Smith R.D. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006, 5:1727-1744.
27. Washburn M.P., Wolters D., Yates J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001, 19:242-247.
28. Immler D., Greven S., Reinemer P. Targeted proteomics in biomarker validation: detection and quantification of proteins using a multi-dimensional peptide separation strategy. Proteomics 2006, 6:2947-2958.
29. Anderson N.L., Anderson N.G., Haines L.R., Hardie D.B., Olafson R.W., Person T.W. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004, 3:235-244.
30. Greenough C., Jenkins R.E., Kitteringham N.R., Pirmohamed M., Park B.K., Pennington S.R. A method for the rapid depletion of albumin and immunoglobulin from human plasma. Proteomics 2004, 4:3107-3111.
31. Pieper R., Su Q., Gatlin C.L., Huang S.T., Anderson N.L., Steiner S. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003, 3:422-432.
32. Nuhse T., Yu K., Salomon A. Isolation of phosphopeptides by immobilized metal ion affinity chromatography. Curr Protoc Mol Biol 2007.
33. Sun X., Chiu J.F., He Q.Y. Application of immobilized metal affinity chromatography in proteomics. Expert Rev Proteomics 2005, 2:649-657.
34. Porath J. Immobilized metal ion affinity chromatography. Protein Expr Purif 1992, 3:263-281.
35. Liang S.S., Makamba H., Huang S.Y., Chen S.H. Nano-titanium dioxide composites for the enrichment of phosphopeptides. J Chromatogr 2006, 1116:38-45.
36. 2 surfaces used in the study of regulated, dynamic protein phosphorylation. J Am Soc Mass Spectrom 2007, 18:1932-1944.
37. Gevaert K., Impens F., Van Damme P., Ghesquiere B., Hanoulle X., Vandekerckhove J. Applications of diagonal chromatography for proteome-wide characterization of protein modifications and activity-based analyses. FEBS J 2007, 274:6277-6289.
38. Terracciano R., Gaspari M., Testa F., Pasqua L., Tagliaferri P., Cheng M.M., et al. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics 2006, 6:3243-3250.
39. Fung E.T. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010, 56:327-329.
40. FDA. 510(k) Substantial equivalence determination decision summary. Accessed August 2011. http://www.accessdata.fda.gov/cdrh_docs/reviews/K081754.pdf.
41. Zhang Z., Bast R., Yu Y., Li J., Sokoll L., Rai A.J., et al. Three biomarkers discovered from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890.
42. Regnier F.E., Skates S.J., Mesri M., Rodriguez H., Težak Ž., Kondratovich M.V., et al. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem 2010, 56:165-171.
43. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=5172,http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=862.2860.
44. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=862.9.
45. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/QualitySystemsRegulations/default.htm.
46. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?FR=862.2570.
47. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=626.
48. http://www.accessdata.fda.gov/cdrh_docs/reviews/K093916.pdf.
49. http://www.accessdata.fda.gov/cdrh_docs/reviews/K043067.pdf.